TICKERNERD
Menu
ZURAZURAHealthcare · Biotechnology

ZURA Stock Forecast: Zura Bio Ltd. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$5.21
−3.16% on the day

The 7 Wall Street analysts covering Zura Bio Ltd. hold a median 12-month price target of $18 — +245.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 32 of 100 as at 12 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$499.3M
Ticker Nerd rank
32 / 100
Median analyst target
$18
Analysts covering
7
Revenue$0.0
Operating income−$29.3M
Net income−$26.3M
Free cash flow−$20.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−11.4%
1M
−6.3%
YTD
−0.6%
1Y
+157.9%
From 52W high
−26.0%
From 52W low
+174.2%
$1.90
$7.04
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ZURA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Zura Bio Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
32 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
94
Volatility
66
Size
53
Value
41
Accruals
41
Quality
37
Issuance
31
Revisions
30
Growth
28

Momentum (94): The shares have been drifting up relative to others.

Growth (28): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ZURA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ZURA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00$25.00Oct 25Jan 26Apr 26Jul 26ZURAHigh $26Median $18Low $11

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
7 Buy0 Hold0 Sell
Low $11Median $18High $26

The green dot is the last close — the median target sits +245.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Aug 2026GuggenheimMaintainsBuy$15 → $20
12 Aug 2026WedbushMaintainsOutperform$15 → $22
8 July 2026William BlairInitiatesOutperform—
8 July 2026William BlairInitiatesOutperform—
1 July 2026WedbushReiteratesOutperform—
1 July 2026WedbushReiteratesOutperform$15
23 Mar 2026Chardan CapitalMaintainsBuy—
20 Mar 2026OppenheimerMaintainsOutperform—
9 Feb 2026WedbushInitiatesOutperform—
14 Nov 2025Chardan CapitalMaintainsBuy—
13 Nov 2025Clear StreetInitiatesBuy—
30 Sept 2025Chardan CapitalMaintainsBuy—
19 Aug 2025HC Wainwright & Co.MaintainsNeutral—
15 Aug 2025Chardan CapitalMaintainsBuy—
15 Aug 2025OppenheimerMaintainsOutperform—
9 May 2025OppenheimerMaintainsOutperform—
3 Apr 2025HC Wainwright & Co.MaintainsNeutral—
26 Mar 2025Chardan CapitalMaintainsBuy—
26 Mar 2025GuggenheimReiteratesBuy—
26 Mar 2025OppenheimerMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ZURA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ZURA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Zura Bio Ltd. returned +157.9% against +17.5% for the S&P 500, dividends included.

ZURA vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300350Oct 25Jan 26Apr 26Jul 26ZURAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ZURA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Zura Bio Ltd. (ZURA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
7.9×

Cheaper than 62% of US stocks

Price / sales
—
Price / book
2.5×

Cheaper than 38% of US stocks

EV / EBITDA
−3.2×

Cheaper than 75% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−51.0%

Higher than 21% of US stocks

Return on assets
−31.2%

Higher than 13% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Zura Bio Ltd. (ZURA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Zura Bio Ltd. has a market value of $499.3M and an enterprise value of $294.1M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$85.7M.

  • Free cash flow in the twelve months to 30 June 2026: −$77.6M.

  • Shares outstanding: 95.4M.

  • Trailing P/E: 7.9×; forward P/E: −8.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Zura Bio Ltd. employs 40 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

ZURA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ZURAZura Bio Ltd.$499.3M
32
ARTVArtiva Biotherapeutics, Inc.$496.6M
38
ENTXEntera Bio Ltd.$491.7M
49
IRDOpus Genetics, Inc.$491.6M
58
OVIDOvid Therapeutics, Inc.$502.1M
67
VOGXVogenx, Inc.$485.9M
1
EIKNEikon Therapeutics, Inc.$483.7M
1

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Zura Bio Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ZURA news & analysis

Zura Bio to Participate in the Cantor Global Healthcare Conference

Business Wire · 31 Aug 2026neutral

Zura Bio announced that members of its management team will participate in the Cantor Global Healthcare Conference in New York, NY, including a fireside chat scheduled for Wednesday, September 9, 2026. The company is a clinical-stage biotechnology firm developing medicines for autoimmune and inflammatory diseases.

Why it matters — A ZURA watcher would care because the management team's participation at a major investor conference offers an opportunity for additional company exposure and investor engagement.

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire · 21 Aug 2026neutral

Zura Bio reported that on August 20, 2026, it granted inducement awards consisting of options to purchase up to 587,000 Class A Ordinary Shares to thirteen newly hired employees. The grants were made under Nasdaq Listing Rule 5635(c)(4).

Why it matters — This item signals Zura's ongoing hiring and equity-based incentive activity, which ZURA watchers may track as part of the company's workforce and compensation developments.

Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates

Business Wire · 11 Aug 2026positive

Zura Bio Limited reported its financial results for the second quarter ended June 30, 2026, and provided recent corporate updates. Management highlighted strong execution across the company's tibulizumab programs, noting that enrollment is now complete.

Why it matters — ZURA watchers would care because the report confirms progress on the company's lead tibulizumab programs and provides a snapshot of its financial standing for the quarter.

FAQ

Frequently asked questions about ZURA stock

What is the ZURA stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Zura Bio Ltd. have a median 12-month price target of $18, with estimates ranging from $11 to $26. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ZURA stock a buy right now?

Of the 7 analysts covering Zura Bio Ltd., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Zura Bio Ltd. 32 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ZURA?

As at 12 Sept 2026, Zura Bio Ltd. ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (94 of 100).

Will ZURA stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +245.5% from the last close, and Ticker Nerd's factor model ranks Zura Bio Ltd. 32 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ZURA stock forecast for 2030?

No analyst covering Zura Bio Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ZURA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $26 over the next 12 months.

How has ZURA stock performed over the past year?

Zura Bio Ltd. returned +157.9% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Zura Bio Ltd. do?

Zura Bio Limited is a clinical-stage biotechnology company focused on developing novel medicines for autoimmune and inflammatory diseases. The company is building a multi-asset immunology pipeline centered on dual-pathway antibodies designed to address immune system imbalance and improve treatment options for patients with serious, underserved conditions.

What is the latest news on ZURA?

The most recent item we track (Business Wire, 31 Aug 2026): "Zura Bio to Participate in the Cantor Global Healthcare Conference". Zura Bio announced that members of its management team will participate in the Cantor Global Healthcare Conference in New York, NY, including a fireside chat scheduled for Wednesday, September 9, 2026. The company is a clinical-stage biotechnology firm developing medicines for autoimmune and inflammatory diseases.

Company

About Zura Bio Ltd.

Zura Bio Limited is a clinical-stage biotechnology company focused on developing novel medicines for autoimmune and inflammatory diseases. The company is building a multi-asset immunology pipeline centered on dual-pathway antibodies designed to address immune system imbalance and improve treatment options for patients with serious, underserved conditions. Its current programs include tibulizumab, torudokimab, and crebankitug, each targeting distinct immune pathways involved in inflammation and autoimmune activity. Zura Bio Limited concentrates on therapeutic areas such as hidradenitis suppurativa, systemic sclerosis, alopecia areata, and other immune-mediated disorders. By advancing differentiated antibody-based therapies, the company plays a specialized role in the biotechnology market as a developer of precision treatments for complex inflammatory diseases. Zura Bio Limited is headquartered in Henderson, Nevada.

CEO Dr. Sandeep Chidambar Kulkarni M.D. · 40 employees · United States · https://zurabio.com